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Abstract 
BACKGROUND AND PURPOSE  
TLR4 signalling contributes to inflammatory cardiovascular diseases, but little is 
known about its role in hypertension and the associated vascular damage. We 
investigated whether TLR4 activation contributes to angiotensin II (AngII)-induced 
hypertension and the associated vascular structural, mechanical and functional 
alterations.  
EXPERIMENTAL APPROACH 
We used aorta and mesenteric arteries from mice infused or not with AngII (1.44 
mg·Kg
-1
·day
-1
, 2 weeks, sc) treated with the neutralizing anti-TLR4 antibody or IgG (1 
µg·day
-1
), and cultured vascular smooth muscle cells (VSMC) from hypertensive rats.  
KEY RESULTS 
Aortic TLR4 mRNA levels were greater in AngII-infused than control mice. Anti-
TLR4 antibody treatment of AngII-infused mice improved: 1) the increased blood 
pressure and MCP-1, TNFα and IL-6 levels; 2) the vascular structural changes; 3) the 
increased vascular stiffness, the diminished wall distensibility, the altered elastin 
structure and the collagen deposition; 4) the altered aortic phenylephrine- and ACh-
induced responses; 5) the increased NOX-1 mRNA levels, superoxide anion production 
and NAD(P)H oxidase activity and the effects of catalase, apocynin, ML-171 and Mito-
TEMPO on vascular responses; and 6) the reduced NO release and the L-NAME effect 
on phenypehrine-induced contraction. In VSMC, the MyD88 inhibitor ST-2825 reduced 
the AngII-induced NAD(P)H oxidase activity; moreover, the TLR4 inhibitor CLI-095 
reduced the AngII-induced increased phospho-JNK1/2 and p65 NF-κB subunit nuclear 
protein expression. 
CONCLUSIONS AND IMPLICATIONS 
TLR4 upregulation by AngII contributes to the inflammation, endothelial 
dysfunction, vascular remodelling and stiffness associated with hypertension by 
mechanisms probably involving oxidative stress. MyD88-dependent activation and 
JNK/NF-κB signalling pathways might contribute to these alterations.  
Key words: TLR4, hypertension, oxidative stress, vascular remodelling, 
endothelial dysfunction  
List of non-standard abbreviations: AngII, angiotensin II; dAUC, differences of 
area under the concentration-response curves; DAMPs, damage-associated molecule 
patterns; ECM, extracellular matrix; HSP, heat shock proteins; IL-6, interleukin-6; IEL, 
internal elastic lamina; KHS, Krebs-Henseleit solution; L-NAME, N
G
-nitro-L-arginine 
methyl ester; ML-171, 2-acetylphenothiazine; MCP-1, monocyte chemoattractant 
protein-1; O2
.-
, superoxide anion; ROS, reactive oxygen species; SHR, spontaneously 
hypertensive rats; TLR4, Toll-like receptor 4; TNFα, tumor necrosis factor α; VSMC, 
vascular smooth muscle cells. 
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Introduction 
Structural alterations or vascular remodelling, increased stiffness and endothelial 
dysfunction are key features of hypertension and are associated to vascular smooth 
muscle cells (VSMC) reorganization, increased extracellular matrix (ECM) deposition 
and altered contractility or impaired endothelium-dependent relaxation (Mulvany, 2008; 
Briones et al., 2010; Rizzoni and Agabiti-Rosei, 2012; Ponticos and Smith, 2014). Both 
endothelial dysfunction and remodelling of small vessels are relevant prognostic factors 
of cardiovascular events in high-risk population (de Ciuceis et al., 2007; Mathiassen et 
al., 2007; Münzel et al., 2008). Therefore, elucidating the mechanisms responsible for 
these alterations is of enormous interest. 
It is recognized that chronic-low grade inflammation has a crucial role in the 
pathogenesis of hypertension (Savoia and Schiffrin, 2006). The role of adaptive 
immunity in the pathogenesis of hypertension has been recently reported (for review, 
see de Ciuceis et al., 2014; Harrison, 2014; Schiffrin, 2014). Angiotensin II (AngII) is 
now considered a proinflammatory mediator in hypertension through mechanisms 
involving reactive oxygen species (ROS) production that contribute to the observed 
vascular alterations. (Touyz, 2005; Briones et al., 2009; Briones and Touyz, 2010). 
However, how the inflammation associated with this pathology is initiated has not been 
fully elucidated. Toll-like receptor 4 (TLR4) is a member of pattern recognition 
receptors which plays an important role mediating inflammatory response (Carpenter 
and O´Neill, 2009; McCarthy et al., 2014). Besides being expressed in immune cells, 
TLR4 is ubiquitously expressed in cells of the cardiovascular system and in fact 
contribution of TLR4 signalling has been proposed in vascular inflammatory 
pathologies such as atherosclerosis, diabetes or metabolic syndrome (den Dekker et al., 
2010; Jialal et al., 2014). Moreover, we and others have recently described an emerging 
role for TLR4 in hypertension. Thus, TLR4 expression is increased in hypertension, and 
this expression seems to be associated with the increased blood pressure (Eiβler et al., 
2011; Bomfin et al., 2012; Marketou et al., 2012; Sollinger et al., 2014; de Batista et 
al., 2014). TLR4 is activated by lipopolysaccharide as well as by non-infectious host-
endogenous compounds (damage-associated molecule patterns, DAMPs), such as heat 
shock proteins (HSP), fibrinogen and tenascin-C, many of which are present in 
hypertension as a consequence of chronic cell injury and death (Tsan and Gao, 2004; 
McCarthy et al., 2014). Furthermore, AngII upregulates TLR4 expression that 
contributes to the proinflammatory effects of this factor (Wolf et al., 2006; Ji et al., 
2009; Yuen et al., 2012). In this sense, we have described that through AT1 receptors 
AngII contributes to the vascular TLR4 upregulation found in spontaneously 
hypertensive rats (SHR) (de Batista et al., 2014). After activation, TLR4 signalling 
might occur via MyD88 (myeloid differentiation factor 88)-dependent or -independent 
pathways that ultimately activate NF-κB, which controls transcription of several 
proinflammatory genes (Carpenter and O´Neill, 2009; Kawai and Akira, 2010). 
Recent studies have demonstrated that TLR4 is involved in the vascular 
dysfunction observed in SHR and N
G
-nitro-L-arginine methyl ester (L-NAME)-induced 
hypertension (Sollinger et al., 2014; de Batista et al., 2014). While the imbalance 
between Th1 effector and the anti-inflammatory Treg lymphocytes in the progression of 
vascular remodelling in hypertension has been proposed (Schiffrin, 2014; de Ciuceis et 
al., 2014; Harrison, 2014), to the best of our knowledge, the involvement of TLR4 in 
the structural and mechanical alterations observed in this pathology has not still been 
explored. Therefore, we investigated whether TLR4 contributes to AngII-induced 
hypertension and the associated vascular structural, mechanical and functional 
alterations focusing on the role of oxidative stress in these alterations. Our findings 
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provide novel evidence that TLR4 mediates AngII-induced hypertension and 
inflammation as well as the vascular functional alterations and remodelling associated 
to this pathology. Our results also suggest that the JNK/NF-κB signalling pathways and 
increased oxidative stress from NAD(P)H oxidase and mitochondria may be implicated 
in these vascular effects through MyD88-dependent activation. 
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Methods 
Animal models  
All procedures were approved by the Ethical Committee of Research of the 
Universidad Autónoma de Madrid, Spain (CEI-UAM 31-759) and are in accordance 
with the guidelines for ethical care of experimental animals of the European 
Community, the current Spanish and European laws (RD 223/88 MAPA and 609/86), 
and the Animal Research: Reporting In Vivo Experiments (ARRIVE) guidelines. 
The following C57BL6 male mice were used: 1) control mice treated with a non-
specific IgG (IgG2a, 1 µg·day
-1
, saline-diluted, i.p., Santa Cruz Biotechnology Inc., 
Dallas, TX, USA); 2) infused with AngII (1.44 mg·Kg
-1
·day
-1
 for 2 weeks, s.c. by Alzet 
osmotic minipumps, Alza Corp., Cupertino, CA, USA) and treated with IgG; 3) infused 
with AngII and treated with the neutralizing anti-TLR4 antibody (rat monoclonal IgG2a, 
1 µg·day
-1
 saline-diluted, i.p., Santa Cruz Biotechnology Inc.). For some experiments, 
control mice treated with anti-TLR4 antibody were also used; treatment did modify 
neither blood pressure nor structural and mechanical parameters of mesenteric arteries 
nor aortic vascular responses (results not shown). Treatments started 24 h prior to AngII 
infusion. Systolic BP was measured by tail-cuff plethysmography. In addition, VSMC 
obtained from adults SHR were also used.  
Tissue preparations 
Animals were euthanized by CO2 and aorta and first order branches of the 
mesenteric artery were dissected free of fat and connective tissue and maintained in cold 
(4°C) Krebs-Henseleit solution (KHS, in mM: 115 NaCl, 25 NaHCO3, 4.7 KCl, 1.2 
MgSO4.7H2O, 2.5 CaCl2, 1.2 KH2PO4, 11.1 glucose, and 0.01 Na2EDTA) bubbled with 
a 95% O2-5% CO2 mixture (pH=7.4). The analyses of vascular structure and function as 
well as NO production were made on the same day. For superoxide anion (O2
.-
) 
production measurement, segments were placed in KHS containing 30% sucrose for 20 
min, transferred to a cryomold containing Tissue Tek OCT embedding medium and 
frozen in liquid nitrogen. For immunofluorescence and histological studies, arterial 
segments were fixed with 4% paraformaldehyde (PFA; in 0.2 M phosphate buffer, 
pH=7.2-7.4) for 1 h and washed in three changes of PBS. After washing, arterial 
segments were frozen as described above. Segments used for gene expression studies 
were immediately frozen in liquid nitrogen. Tissues were kept at -70°C until the day of 
the experiments. The hearts were removed to assess cardiac hypertrophy. For this, the 
ratio between the left ventricular wet weight and the length of the tibia was calculated. 
Cell culture 
Primary cultures of VSMC were obtained from thoracic aortas from 5 months-old 
SHR using the explant method (Martín et al., 2012). Cells were identified as VSMC by 
morphological and growth characteristics and by positive immunocytochemical staining 
with a specific monoclonal anti-α-actin antibody (Sigma Chemical Co., St Louis, MO, 
USA). For experiments, cells from passages 2 to 5 were rendered quiescent by 
incubation in DMEM containing 0.2% FBS for 24 h. Cells were stimulated with 100 
nM AngII (for the times indicated in the results section), with or without pretreatment 
for 1 h with the MyD88 inhibitor ST-2825 (20 µM) or the TLR4 inhibitor CLI-095 (1 
µM).  
Pressure myography 
The structural and mechanical properties of small mesenteric arteries were studied 
with a pressure myograph (Danish Myo Tech, Model P100, J.P. Trading I/S, Aarhus, 
Denmark), as described (Briones et al., 2009). Briefly, vessels were placed in calcium-
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free KHS (0Ca
2+
; omitting calcium and adding 1 mM EGTA) and a pressure-diameter 
curve was obtained by increasing intraluminal pressure in 20 mmHg steps from 3 to 120 
mmHg. Internal and external diameters were continuously measured under passive 
conditions (Di0Ca, De0Ca) for 3 min at each intraluminal pressure. Finally, arteries were 
set to 45 mmHg in 0Ca
2+
-KHS and then pressure-fixed with 4% phosphate buffered 
PFA at 37°C for 60 min and kept at 4°C for confocal microscopy studies. 
From internal and external diameter measurements in passive conditions the 
following structural and mechanical parameters were calculated: 
Wall thickness (WT) = (De0Ca − Di0Ca )/2 
Wall:lumen = (De0Ca − Di0Ca)/2Di0Ca 
Incremental distensibility represents the percentage of change in the arterial 
internal diameter for each mmHg change in intraluminal pressure, and was calculated 
according to the formula: 
Incremental distensibility = ∆Di0Ca/(Di0Ca × ∆P) × 100 
Circumferential wall strain (ε) = (Di0Ca - D00Ca)/D00Ca, where D00Ca is the internal 
diameter at 3 mmHg and Di0Ca is the observed internal diameter for a given 
intravascular pressure, both measured in 0Ca
2+
 medium.  
Circumferential wall stress (σ) = (P × Di0Ca)/(2WT), where P is the intraluminal 
pressure (1 mmHg = 1.334 × 10
3
 dynes·cm
-2
) and WT is the wall thickness at each 
intraluminal pressure measured in 0Ca
2+
-KHS. 
Arterial stiffness independent of geometry is determined by the Young’s elastic 
modulus (E =stress/strain). The stress-strain relationship is non-linear; therefore, it is 
more appropriate to obtain a tangential or incremental elastic modulus (Einc) by 
determining the slope of the stress-strain curve (Einc=δσ/δε). Einc was obtained by fitting 
the stress-strain data from each animal to an exponential curve using the equation: σ 
=σorige
βε
, where σorig is the stress at the original diameter (diameter at 3 mmHg). Taking 
derivatives on the equation presented earlier, we see that Einc = βσ. An increase in β 
implies an increase in Einc, which means an increase in stiffness. 
Confocal microscopy study of nuclei distribution  
Quantification of nuclei distribution was analyzed in pressure-fixed intact 
mesenteric segments, as described (Arribas et al., 1997). Briefly, arteries were 
incubated with the nuclear dye Hoechst 33342 (Sigma Chemical Co.) (0.01 mg·ml
-1
) 
and visualized with a Leica TCS SP2 confocal system (Leica Microsystems, Wetzlar, 
Germany, ×40 objective, zoom ×3.5). Metamorph image analysis software (Universal 
Imaging, Molecular Devices Corp., Downingtown, PA, USA) was used for 
quantification. 
To allow comparisons the following calculations were performed on the basis of 
1-mm-long segments: artery volume (mm
3
) [volume = wall CSA (mm
2
) × 1 mm]; total 
number of adventitial and smooth muscle cells (cell n = n of nuclei per stack × n of 
stacks per artery volume); total number of endothelial cells [calculated per luminal 
surface of 1-mm-long artery; luminal surface area = 2π x diameter (mm) × 1 mm /2]. 
Organization of internal elastic lamina 
The elastin organization within the internal elastic lamina (IEL) was studied in 
segments of small mesenteric arteries, using fluorescence confocal microscopy based on 
the autofluorescent properties of elastin (Ex 488 nm and Em 500-560 nm), as previously 
described (Briones et al., 2003). Briefly, intact pressure-fixed segments were visualized 
with a Leica TCS SP2 confocal system. From each stack of serial images, individual 
projections of the IEL were reconstructed, and total fenestrae number and fenestrae area 
were measured using Metamorph Image Analysis Software.  
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Collagen determination  
Mesenteric arteries were cut into 5 µm sections using a cryostat. Collagen was 
quantified in Picro-sirius red-stained sections [0.1% (wt·vol
-1
) Sirius red 3FB in 
saturated aqueous picric acid for 30 min with gentle agitation]. Three-four sections from 
each animal were analyzed under microscopy transmitted light (Leica DM 2000, Leica 
Microsystems) using an Image System Analysis (Leica LAS Image Analysis, Leica 
Microsystems). The area of collagen in the media layer was identified after excluding 
perivascular fibrosis of the vessel as the ratio of collagen deposition to the total media 
area. 
Histological analysis  
Cross sections (14 µm) from aortas were stained with hematoxylin-eosin. All 
images were acquired at room temperature using a microscope (Leica DM 2000). 
Morphometric determinations of the lumen and vessel areas were performed by using 
Metamorph Image Analysis Software. All microscopic images of the sections were 
traced for the calculations of the areas. To determine the luminal area, the cross-
sectional area enclosed by the IEL was corrected to a circle by applying the form factor 
l
2
/4π to the measurement of the IEL, where l is the length of the lamina. Vessel area was 
determined by the cross-sectional area enclosed by the external elastic lamina corrected 
to a circle, applying the same form factor (l
2
/4π) to the measurement of the external 
elastic lamina. The media area was calculated as the difference between the corrected 
vessel and luminal areas. Internal and external diameters were calculated from luminal 
and vessel areas, respectively. This method avoids miscalculations of areas caused by 
eventual collapse of the immersion-fixed arteries. 
Vascular function 
Reactivity of mice aorta was studied in a wire myograph. After a 30-min 
equilibration period in oxygenated KHS, arterial segments were stretched to their 
optimal lumen diameter for active tension development. Segments contractility was then 
tested by an initial exposure to a high-K
+
 solution (K
+
-KHS, 120 mM). The presence of 
endothelium was determined by the ability of 10 µM ACh to relax arteries precontracted 
with phenylephrine at approximately 50% the K
+
-KHS contraction. Afterwards, a single 
concentration-response curve to ACh (1 nM-10 µM), phenylephrine (1 nM-10 µM) and 
diethylamine NONOate (DEA-NO, 3 nM-10 µM) was performed. The effects of the 
hydrogen peroxide detoxificant catalase (1000 U·ml
-1
), the NAD(P)H oxidase inhibitor 
apocynin (0.3 mM), the selective NOX-1 inhibitor ML-171 (2-acetylphenothiazine, 0.5 
µM), the mitochondrion-targeted SOD2 mimetic Mito-TEMPO (0.5 µM) or the non-
selective inhibitor of NO synthesis, L-NAME (100 µM) on phenylephrine- or ACh-
induced responses were analyzed. These drugs were incubated 30 min prior to 
phenylephrine. 
Immunofluorescence  
TLR4 in aorta was immunolocalized as described (de Batista et al., 2014). Briefly, 
frozen transverse sections (14 µm) were incubated with a polyclonal antibody against 
TLR4 (1:100, Santa Cruz Biotechnology Inc.) in PBS containing 2% bovine serum 
albumin for 1 h at 37ºC in a humidified chamber. After washing, rings were incubated 
with the secondary antibody goat anti-rat (1:200) IgG labelled with alexa fluor-546 dye 
(Molecular Probes Inc., Eugene, OR, USA), for 1 h at 37ºC in a humid box. Nuclei were 
stained with 0.01 mg·ml
-1
 Hoechst 33342. Immunofluorescent signals were viewed 
using an inverted Leica TCS SP2 confocal laser-scanning microscope with oil 
immersion lens. The specificity of the immunostaining was evaluated by omission of 
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the primary antibody and processed as above. Under these conditions, no staining was 
observed in the vessel wall. 
Immunofluorescence was also used to detect p65 NF-κB subunit nuclear protein 
expression in cultured VSMC stimulated with AngII (100 nM, 45 min) after treatment 
or not with CLI-095 (1 µM, 1h), as described (Pérez-Girón et al., 2014). Cells were 
incubated overnight at 4°C with a rabbit polyclonal primary antibody against p65 
(1:250, Santa Cruz Biotechnology). After washing, cells were incubated with a FITC-
conjugated goat anti-rabbit secondary antibody (1:200, Molecular Probes, Life 
Technologies Ltd, Paisley, UK). Then, cells were counterstained for 15 min with DAPI 
(1:10,000, Invitrogen Life Technologies) and visualized under a fluorescence 
microscope (Zeiss, Axioplan 2, Carl Zeiss Microscopy, LLC, Thornwood, NY, USA). 
At least three independent experiments were performed. 
Quantitative PCR real time (qRT-PCR) assay 
mRNA levels were determined in mice aortic homogenates. Total RNA was 
obtained using TRI Reagent (Sigma Chemical Co.) according to the manufacturer's 
recommendations. A total of 1 µg of DNAse I treated RNA was reverse-transcribed 
using the High Capacity cDNA Archive Kit (Applied Biosystems, Foster City, CA, 
USA) in a final volume of 10 µl. qPCR was performed using the fluorescent dye 
SyBRGreen (iTaq FAST SyBRGreen Supermix with ROX, Bio-Rad, USA). β2-
microglobulin (Rn00560865_m1, Applied Biosystems) or 36B4 were used as internal 
controls. All qPCRs were performed in duplicate. Primer sequences are: for TLR4, FW: 
TGTGCCTTCAAAACATGACTGG, RV: CTCCCAAGATCAACCGATGG; p22phox, 
FW: ATCTGTCTGCTGGAGTAT, RV: CGTAGTAATTCCTGGTGAG; NOX-1, FW: 
CAGCGTGCCGACAACAAG; RV: CCAGCCAGTGAGGAAGAGAC; TNF-α, FW: 
CCACGCTCTTCTGTCTACTG, RV: TGAGGGTCTGGGCCATAGA; MCP-1 
(monocyte chemoattractant protein-1), FW: CATCCACGTGTTGGCTCA, RV: 
GATCATCTTGCTGGTGAATGAGT; IL-6, FW: TGATGGATGCTACCAAACTGG, 
RV: TTCATGTACTCCAGGTAGCTATGG; 36B4, FW: 
AGATGCAGCAGATCCGCAT, RV: GTTCTTGCCCATCAGCACC. qRT-PCR was 
carried out in an ABI PRISM 7000 Sequence Detection System (Applied Biosystems) 
using the following conditions: 2 min 50°C, 10 min 95°C and 40 cycles: 15 s 95ºC, 1 
min 60ºC. At the end of the PCR, melting curve analysis was performed to show PCR 
product specificity. To calculate the relative index of gene expression, we employed the 
2
−∆∆Ct
 method using untreated samples as calibrator.  
Measurement of O2
.-
 production 
The oxidative fluorescent dye dihydroethidium (DHE) was used to evaluate 
production of O2
.-
 in situ, as previously described (Martínez-Revelles et al., 2013). 
Briefly, aortic sections were incubated in buffer containing DHE (2 µM, 30 min, 37ºC) 
and then viewed by a fluorescent laser-scanning confocal microscope (Leica TCS SP2; 
Ex 561 and Em 610 nm), using the same imaging settings in each case. As a negative 
control, parallel sections were preincubated with tempol (100 µM). In these conditions, 
no staining was observed in the vascular wall. O2
.-
 production was quantitatively 
analyzed with MetaMorph Image Analysis Software. 
NAD(P)H oxidase activity 
The lucigenin-enhanced chemiluminescence assay was used to determine the 
superoxide anion generated by NAD(P)H oxidase activity, as described (Pérez-Girón et 
al., 2014). Tissues were homogenized in a lysis buffer (in mM: KH2PO4 50, ethylene 
glycol tetraacetic acid 1, sucrose 150, pH=7.4). The reaction was started by the addition 
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of NAD(P)H (0.1 mM) to the suspension containing sample, lucigenin (5 µM), and 
assay phosphate buffer. The luminescence was measured in a plate luminometer (Auto-
Lumat LB 953, Berthold Technologies GmbH & Co. KG, Bad Wildbad, Germany). 
Buffer blank was subtracted from each reading. Activity was expressed as relative light 
units·mg
-1
 protein. Samples from control+IgG-treated mice or untreated cells were used 
as controls, and variations of activity were calculated as the amount relative to controls. 
Nitric oxide release 
NO production was determined in aortic segments with the fluorescent probe 4,5-
diaminofluorescein (DAF-2), as described (Martínez-Revelles et al., 2013). Briefly, 
aortic segments were incubated with DAF-2 (2 µM) for 45 min. Afterwards, basal and 
ACh-stimulated NO release were measured using a spectrofluorimeter (FLUOstar 
OPTIMA BMG Labtech). To avoid variations in fluorescence among the different days, 
all experimental conditions were measured each day. The amount of NO released was 
expressed as arbitrary units·mg
-1
 tissue. 
Western blot analysis  
Protein expression was determined in whole cell lysates (20 µg protein) or nuclear 
extracts (15 µg protein) by Western blot, as described. Proteins were separated by 15% 
SDS-PAGE and then transferred to polyvinyl difluoride membranes overnight. 
Membranes were incubated with rabbit polyclonal antibody for p-JNK1/2 (1:1,000, Cell 
Signaling Technology Inc, Danvers, MA, USA) or p65 (1:1,000). Immunoreactive 
bands were visualized using fluorescent secondary antibodies from rabbit (1:5,000, Bio-
Rad, Laboratories, Hercules, CA, USA) and ECF Plus Western blot analysis system 
(GE Healthcare; Little Chalfont, UK). Signals on the immunoblot were quantified using 
the Typhoon 9210 quantification software (GE Healthcare). The same membrane was 
used to determine JNK (monoclonal antibody anti-JNK, 1:1,000, Cell Signaling 
Technology Inc) in cellular lysates and Histone-3 (rabbit polyclonal antibody anti-
Histone-3, 1:500, Santa Cruz Biotechnology) in nuclear extracts. Results are expressed 
as the ratio between signals on the immunoblot corresponding to the different proteins 
and total JNK or Histone-3 in the same preparation. To compare results for protein 
expression within the same experiment and with others, we assigned a value of 1 in 
each gel to the expression of unstimulated control cells and used that value to calculate 
the relative density of other bands from the same gel. 
Statistical analysis and drugs  
Vasoconstrictor responses were expressed as a percentage of the tone generated 
by K
+
-KHS. Vasodilator responses were expressed as the percentage of the previous 
tone induced by phenylephrine in each case. The maximum response (Emax) and pD2 
values were calculated by non-linear regression analysis of each individual 
concentration-response curve using GraphPad Prism Software (San Diego, CA, USA). 
To compare the effect of L-NAME on the response to phenylephrine in segments from 
the three groups, results were expressed as the differences of areas under the 
concentration-response curves (dAUC) in the control and experimental situations. 
AUCs were calculated from the individual concentration-response curve plots using 
GraphPad Prism Software; differences were expressed as the percentage of the AUC of 
the corresponding control situation. 
All values are expressed as mean ± SEM of the number of animals or different 
cultures (each obtained from three different animals) used. Results were analyzed by 
using unpaired Student’s t-test or two-way ANOVA followed by Bonferroni’s post hoc 
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test or Mann-Whitney nonparametric test by using GraphPad Prism Software. A P < 
0.05 was considered significant. 
l-phenylephrine hydrochloride, ACh chloride, catalase, apocynin, L-NAME, and 
ML-171 were purchased from Sigma Chemical Co, mito-TEMPO from Santa Cruz 
Biotechnology Inc., DHE from Invitrogen, CLI-095 from Invivogen (San Diego, CA, 
USA) and ST-2825 from MedChem Express (Princeton, NJ, USA). All drugs were 
dissolved in distilled water, except for CLI-095 and ST-2825, which were dissolved in 
dimethyl sulfoxide (DMSO); 10 µl of DMSO did not have any effect on VSMC. 
The receptor nomenclature conforms to BJP´s Concise Guide to Pharmacology 
according to Alexander et al. (2013). 
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Results 
TLR4 mediates AngII-induced hypertension and inflammation 
TLR4 mRNA levels were greater in aortic segments from AngII-infused mice 
when compared with controls (Figure 1A); TLR4 expression was increased in all layers 
of the vascular wall (Figure 1A).  
Treatment with anti-TLR4 partially prevented the increased SBP observed in 
AngII-infused mice (Figure 1B), although neither body weight (data not shown) nor left 
ventricular hypertrophy were affected (Figure 1C).  
Aortic segments from AngII-infused mice showed increased mRNA levels of 
TNFα, IL-6 and MCP-1 that were prevented by anti-TLR4 treatment (Figure 1D). 
TLR4 mediates vascular remodelling and mechanical alterations 
In small mesenteric arteries from AngII-infused mice, vessel and lumen diameters 
were reduced, while wall thickness and wall:lumen ratio were increased when compared 
with controls (Figure 2A-D). Treatment of AngII-infused mice with anti-TLR4 antibody 
improved these structural parameters (Figure 2A-D); the treatment also improved the 
reduced number of smooth muscle and endothelial cells observed in mesenteric arteries 
from AngII-infused mice (Figure 2E).  
AngII infusion reduced incremental distensibility (Figure 3A) and increased 
vessel stiffness of mesenteric arteries, as shown by the leftward shift of the stress-strain 
relationship and the larger β value (Figure 3B) that were prevented by anti-TLR4 
antibody treatment (Figure 3A,B). AngII reduced the number and size of fenestrae in 
the IEL (Figure 3C) and increased the collagen deposition (Figure 3D). Anti-TLR4 
treatment improved fenestrae size and decreased collagen deposition (Figure 3C,D).  
In aorta from AngII-infused mice, the media thickness, media:lumen ratio and 
cross-sectional area were increased when compared with controls; treatment with anti-
TLR4 antibody prevented these structural alterations (Figure 4). 
TLR4 mediates alterations on vascular function 
Phenylephrine-induced contractile responses were greater in aortic segments from 
AngII-infused than control mice and these responses were reduced by anti-TLR4 
antibody treatment (Figure 5A). Treatment also improved the reduced ACh-induced 
endothelium-dependent vasodilatation observed in aorta from AngII-infused mice 
(Figure 5B). Endothelium-independent relaxation induced by DEA-NO was similar in 
the three groups (Figure 5C).  
TLR4 mediates vascular ROS production  
The increased AngII-induced ROS production may contribute to the vascular 
alterations occurring in hypertension (Briones and Touyz, 2010; Virdis et al., 2011). As 
expected, O2
.-
 production was greater in the aortic wall from AngII-infused than control 
mice; this was particularly evident in adventitia and media layers (Figure 6A). Aortic 
NAD(P)H oxidase activity (Figure 6B) and p22phox and NOX-1 mRNA levels (Figure 
6C) were also greater in AngII-infused than control mice. Anti-TLR4 antibody 
treatment prevented the increased O2
.-
 production, NAD(P)H oxidase activity and NOX-
1 mRNA levels, without modifying p22phox levels (Figure 6).  
We have previously described that AngII increases oxidative stress in VSMC 
through TLR4 activation (de Batista et al, 2014). Herein we observed that AngII (1 h)-
induced NAD(P)H oxidase activity was reduced by the MyD88 inhibitor ST-2825 
(Figure 7A). We have also reported that AngII increases oxidative stress in VSMC 
through JNK1/2 MAPK and NF-κB (Pérez-Girón et al., 2014). The AngII (10 min)-
Page 11 of 41
British Pharmacological Society
British Journal of Pharmacology
For Peer Review
induced JNK1/2 phosphorylation was reduced by the TLR4 inhibitor CLI-095 (Figure 
7B). In addition, the increased nuclear expression and cytosol to the nucleus 
translocation of the p65 NF-κB subunit induced by AngII (45 min) was also reduced by 
CLI-095 (Figure 7C,D).  
TLR4 mediates the contribution of oxidative stress to altered vascular function 
We then assessed whether the increased ROS production associated with TLR4 
upregulation contributes to the hypertension-associated vascular dysfunction. Catalase, 
apocynin, ML-171 and Mito-TEMPO did not affect phenylephrine-induced contraction 
in control mice, but they reduced those responses in AngII-infused mice; treatment of 
AngII-infused mice with the anti-TLR4 antibody abolished the inhibitory effect of the 
four antioxidants (Figure 8). Similarly, catalase, apocynin, ML-171 and Mito-TEMPO 
increased ACh-induced relaxation only in AngII-infused mice; anti-TLR4 antibody 
treatment abolished these effects (Figure 9). Altogether, these results suggest that TLR4 
increased oxidative stress that would contribute to the impaired vascular function 
observed in hypertensive mice. 
TLR4 reduces NO release and its participation in phenylephrine contraction 
Thereafter, we evaluated the effects of the anti-TLR4 antibody treatment on the 
vascular NO release and its contribution to vasoconstrictor responses. In aorta from 
AngII-infused mice we observed a reduced NO release that was normalized by anti-
TLR4 treatment (Figure 10A). Furthermore, the NOS inhibitor L-NAME leftward 
shifted the concentration-response curve to phenylephrine more in segments from 
control than AngII-infused mice; th  anti-TLR4 antibody treatment restored this effect 
(Figure 10B and Table 1), indicating that the decreased NO involvement to 
phenylephrine contraction after AngII infusion is restored by TLR4 blockade. 
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 Discussion 
The results of the present study demonstrate, for the first time, that upregulation 
of TLR4 by AngII participates in the pathogenesis of hypertension by affecting, not 
only the function, but also the structure and the mechanical properties of the vasculature 
by mechanisms likely involving oxidative stress. MyD88-dependent mechanisms and 
the JNK/NF-κB signalling pathways might contribute to these effects. 
Hypertension has been described as an inflammatory disease in which the 
inadequate activation of immune system may contribute to its pathophysiology (Savoia 
and Schiffrin, 2006; de Ciuceis et al., 2014; Harrison, 2014; McCarthy et al., 2014; 
Schiffrin, 2014; Virdis et al., 2014). The role of adaptive immunity as contributor of 
hypertension has been widely reported. Thus, subsets of T lymphocytes have been 
involved in the development of hypertension and vascular remodelling in different 
hypertension models (de Ciuceis et al., 2014; Harrison, 2014; Schiffrin, 2014; Virdis et 
al., 2014). Moreover, in the last years, activation of TLR4 has become a new research 
focus because of evidence that TLR4 is upregulated in hypertension contributing to its 
occurrence (Eiβler et al., 2011; Bomfin et al., 2012; de Batista et al., 2014; Sollinger et 
al., 2014). The increased expression of TLR4 by AngII is one of the proposed 
mechanisms explaining the involvement of this receptor in hypertension. Thus, AngII 
induces inflammatory responses via TLR4 activation. In this sense, in VSMC AngII, 
through AT1 receptors, activates TLR4 leading to ERK1/2 and NF-κB activation and 
hence inflammatory response (Ji et al., 2009); moreover, osteocalcin-induced AngII 
release activates PKCδ/TLR4/ROS/cyclooxygenase-2 signalling cascade that 
contributes to vascular fibroblasts transformation to myofibroblasts (Yuen et al., 2012). 
Recently we have shown that treatment with an AT1 receptor blocker reduced the 
increased TLR4 levels in SHR (de Batista et al., 2014). Herein we observed that AngII 
infusion increased aortic TLR4 expression. More importantly, anti-TLR4 antibody 
treatment prevented the increased blood pressure and vascular proinflammatory 
cytokine levels, confirming the role of TLR4 to the AngII-induced hypertension and the 
associated inflammation. In agreement, in SHR this treatment reduced blood pressure 
(Bomfim et al., 2012; de Batista et al., 2014) and the increased vascular 
proinflammatory cytokine levels (Bomfim et al., 2015). Further experiments are 
necessary to ascertain the exact mechanisms by which AngII upregulates TLR4 
signalling pathway in our hypertension model. 
The role of TLR4 in hypertension might rely on its effects on vascular structure 
and mechanical properties. TLR4 is involved in the outward arterial remodelling after 
atherosclerotic plaque formation (Hollestelle et al., 2004) and TLR through MyD88-
dependent mechanisms contributes to the flow-mediated inward remodelling of conduit 
arteries (Tang et al., 2008). Furthermore, TLR4 gene Asp299Gly polymorphism is 
associated with increased carotid artery compliance in young adults (Hernesniemi et al., 
2008). Our study provides evidence that TLR4 blockade prevents AngII-induced 
vascular remodelling and mechanical alterations, which might further contribute to the 
anti-hypertensive effects of the anti-TLR4 antibody treatment. Of note, these effects on 
vessel structure are observed in both conductance and resistance arteries, as 
demonstrated by the decreased wall:lumen ratio and wall thickness, which are well-
known predictors of cardiovascular risk (Rizzoni and Agabiti-Rosei, 2012). 
Normalization of vessel structure by anti-TLR4 antibody treatment was achieved by 
improvement of cell number, which is reduced after AngII (Briones et al., 2009). 
Moreover, TLR4 blockade prevented the AngII-induced increased collagen deposition 
and altered elastin structure, probably accounting for the restored wall:lumen ratio and 
the diminished vessel stiffness observed in response to anti-TLR4 treatment. 
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Accordingly, in human VSMC the endogenous ligand for TLR4 HSP70 increases 
fibronectin and collagen type-I (González-Ramos et al., 2013). Besides improving 
vascular structure and mechanics, anti-TLR4 treatment normalized contractile responses 
and endothelial function in aortic segments from AngII-infused mice, in agreement with 
studies in SHR (Bomfin et al., 2012; de Batista et al., 2014). Moreover, we herein 
demonstrate that anti-TLR4 treatment also prevented the decreased endothelial cells 
number induced by AngII, thus providing a novel mechanism for endothelial 
improvement after TLR4 blockade. 
One of the mechanism by which TLR4 blockade might prevent hypertension 
development and improve the vascular alterations found in AngII-infused mice is by 
reducing oxidative stress. Earlier studies described that antioxidants prevented 
hypertension development and structural alterations of both resistance and conductance 
arteries in AngII-infused mice (Virdis et al., 2004; Martínez-Revelles et al., 2013). The 
mechanisms responsible for the vascular alterations induced by increased ROS 
production include VSMC proliferation and migration, oxidation of matrix 
metalloproteinases and generation of matrix proteins such as collagen (Virdis et al., 
2004; Briones et al., 2009; Drummond et al., 2011). Furthermore, the increase of ROS 
has been extensively reported to be responsible for endothelial dysfunction in 
hypertension (Briones and Touyz, 2010; Virdis et al., 2011). In addition, increased ROS 
production by TLR4 pathway contributes to the AngII effects on mesangial cells 
apoptosis and fibroblasts differentiation (Lv et al., 2009; Yuen et al., 2012). Herein, we 
found that anti-TLR4 antibody treatment reduced the increased NOX-1 expression, 
NAD(P)H oxidase activity and superoxide anion production observed in aorta from 
AngII-infused mice. Additionally, this treatment also abolished the effect of different 
antioxidants on both vasoconstrictor and vasodilator responses, confirming that TLR4 
contributes to the endothelial dysfunction in AngII-induced hypertension by increasing 
oxidative stress, as suggested recently in other hypertension models (de Batista et al., 
2014; Sollinger et al., 2014). Our results point to both NAD(P)H oxidase and 
mitochondria as sources for the TLR4-induced oxidative stress. As a result of oxidative 
stress reduction by anti-TLR4 antibody treatment, NO bioavailability might be 
increased. Thus, TLR4 blockade increases NO release and its contribution to the 
phenylephrine-induced vasoconstriction in AngII-infused mice. Accordingly, in obese 
and diabetic mice, TLR4 activation increases ROS levels leading to a reduced NO-
production and bioavailability (Liang et al., 2013). The increased NO would also be 
related to the above mentioned increased number of endothelial cells. Altogether, our 
results suggest that oxidative stress reduction by TLR4 blockade might account for the 
beneficial effects not only on the functional but also on the structural and mechanical 
vascular alterations. Although the role of oxidative stress after TLR4 activation on 
vascular remodelling in hypertension has not been previously explored, superoxide-
initiated inflammation is necessary for MyD88-dependent inward remodelling of 
conduit arteries induced by flow (Tang et al., 2008). Interestingly, TLR4 activation 
contributes to the vascular dysfunction associated with hypertension in SHR by 
cyclooxygenase-dependent mechanisms (Bomfim et al., 2012). Contractile prostanoids 
from COX-2 contribute to hypertension and also to the functional alterations observed 
in AngII-infused mice and this is in part dependent on ROS (Martínez-Revelles et al., 
2013). Therefore, it is possible that by affecting oxidative stress status, TLR4 also 
modulates the COX pathway and its contribution to the vascular alterations associated 
with our hypertension model.  
TLR4 signals through different adaptor proteins, mainly MyD88, ultimately 
activating NF-κB which promotes transcription of different proinflammatory genes 
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(Kawai and Akira, 2010). Another signalling pathway recruited by TLR4 activation via 
MyD88-dependent pathway is the MAPK cascade (Kawai and Akira, 2010). Previously 
we have shown that JNK and NF-κB contributes to the AngII-induced oxidative stress 
(Pérez-Girón et al., 2014). Herein we found, in VSMC, that AngII-induced NAD(P)H 
oxidase activity was reduced by a specific MyD88 inhibitor. Additionally, the TLR4 
antagonist CLI-095 reduced the AngII-induced increased p65 nuclear expression and 
JNK1/2 phosphorylation. Altogether, our results suggest that after TLR4 upregulation, 
through the MyD88-dependent signalling pathway, AngII activates NF-κB/JNK, which 
would contribute to the increased oxidative stress and inflammation occurring in 
hypertension. Accordingly, Bonfim et al. (2015) have recently shown in SHR 
mesenteric arteries that TLR4 signalling is activated, leading to activation of 
MyD88/NF-κB pathway.  
In conclusion, TLR4 upregulation by AngII contributes to the inflammation, 
endothelial dysfunction, vascular remodelling, extracellular matrix alterations and 
vascular stiffness associated with hypertension. These effects might be mediated by the 
MyD88/NF-κB/JNK pathways and increased oxidative stress from NAD(P)H oxidase 
and mitochondria. Although the role of adaptive immunity and T lymphocytes on 
vascular remodelling has been established (de Ciuceis et al., 2014; Harrison, 2014; 
Schiffrin, 2014; Virdis et al., 2014), to the best of our knowledge, this is the first time 
that the TLR4 signalling pathway is described to contribute to the vascular structural 
and mechanical alterations observed in hypertension. The fact that TLR is expressed not 
only in the immune but also in vascular cells allows to suggest that TLR4 might be the 
link between low-grade inflammation, vascular remodelling and hypertension. The 
current model is that in hypertension, the elevated circulating levels of several 
compounds which act as DAMPs, such as AngII, after being recognized by TLRs on 
antigen-presenting cells, would originate the activation of T cells; the release of 
cytokines and chemokines causes inflammation and subsequently vascular damage 
through several mechanisms, including oxidative stress. This results in increased blood 
pressure, leading to further damage which would increase the release of DAMPs, 
creating a positive feed-back loop which contributes to the maintenance of hypertension 
(de Ciuceis et al., 2014; Harrison, 2014; Schiffrin, 2014). Therefore, our observations 
open new antihypertensive therapeutic perspectives using agents that interfere with the 
TLR4 signalling pathway.  
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Figure legends 
Figure 1. Increased TLR4 contributes to hypertension and inflammation in AngII-
infused mice. (A) TLR4 mRNA levels and representative fluorescent confocal 
photomicrographs (×40 objective) of TLR4 immunolocalization in aortic segments from 
mice treated with a non-specific IgG and from mice treated with AngII plus a non-
specific IgG. Image size: 375 x 375 µm. Positive immunostaining is indicated by arrows 
and the insets are magnified images of indicated areas. (B) Systolic BP (SBP), (C) left 
ventricular hypertrophy and (D) mRNA levels of MCP-1, IL-6 and TNFα in mice 
treated with a non-specific IgG, with AngII plus a non-specific IgG or with AngII plus 
anti-TLR4 antibody. *P < 0.05 vs Control + IgG, 
#
P < 0.05 vs AngII + IgG. n=6-16. 
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Figure 2. TLR4 inhibition improves structural alterations in mesenteric resistance 
arteries from AngII-infused mice. Vessel and lumen diameter (A,B), wall thickness 
(C), wall:lumen ratio (D) and total number of adventitial, smooth muscle and 
endothelial cells (E) in small mesenteric arteries from mice treated with a non-specific 
IgG, with AngII plus a non-specific IgG or with AngII plus anti-TLR4 antibody. *P < 
0.05 vs Control + IgG, 
#
P < 0.05 vs AngII + IgG. n=6-14. 
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Figure 3. TLR4 inhibition improves mechanical alterations in mesenteric 
resistance arteries from AngII-infused mice. Incremental distensibility (A) and 
stress-strain relationship and β values (B) in mesenteric arteries from mice treated with 
a non-specific IgG, with AngII plus a non-specific IgG or with AngII plus anti-TLR4 
antibody. (C) Representative confocal projections and quantification of fenestra area 
and total number of fenestra of the internal elastic lamina of mesenteric arteries from the 
three groups of mice. Projections were obtained from serial optical sections captured 
with a fluorescence confocal microscope (×40 objective, zoom ×7.10); image size: 52.8 
x 52.8 µm. (D) Representative images and quantitative analysis of collagen content in 
the media layer from transversal sections of mesenteric arteries. Images were captured 
with a light microscope (×40 objective); image size: 310.9 x 233.1 µm. *P < 0.05 vs 
Control + IgG, 
#
P < 0.05 vs AngII + IgG. n=6-14. 
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Figure 4. TLR4 inhibition improves structural alterations in aorta from AngII-
infused mice. (A) Representative photographs of hematoxylin-eosin aortic sections 
from mice treated with a non-specific IgG, with AngII plus a non-specific IgG or with 
AngII plus anti-TLR4 antibody. Images were captured with a light microscope (×10 
objective); image size: 2.37 x 1.88 mm. (B) Media thickness, (C) media:lumen ratio and 
(D) cross-sectional area (CSA) in aorta from the three groups of mice. *P < 0.05 vs 
Control + IgG, 
#
P < 0.05 vs AngII + IgG. n=7-8. 
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Figure 5. TLR4 inhibition improves vasoconstrictor and vasodilator responses in 
aorta from AngII-infused mice. Concentration-response curves to phenylephrine (Phe) 
(A), ACh (B) and diethylamine NONOate (DEA-NO) (C) in aorta from mice treated 
with a non-specific IgG, with AngII plus a non-specific IgG or with AngII plus anti-
TLR4 antibody. *P < 0.05 vs Control + IgG, 
#
P < 0.05 vs AngII + IgG. n=12-17. 
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Figure 6. TLR4 inhibition reduces the increased oxidative stress in aorta from 
AngII-infused mice. (A) Representative fluorescent confocal photomicrographs and 
quantification in the media and in the adventitia of vascular superoxide anion 
production in aortic segments from mice treated with a non-specific IgG, with AngII 
plus a non-specific IgG or with AngII plus anti-TLR4 antibody. Vessels were labelled 
with the oxidative dye dihydroethidium and view by using a fluorescence confocal 
microscope (×40 objective). Image size 375 x 375 µm. (B) Basal NAD(P)H oxidase 
activity and (C) NOX-1 and p22phox mRNA levels in aorta from the three groups of 
mice. *P < 0.05 vs Control + IgG, 
#
P < 0.05 vs AngII + IgG. n=5-8. 
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Figure 7. AngII activates Myd88, JNK and NF-κB in vascular smooth muscle cells 
(VSMC). (A) Effect of ST-2825 (20 µM, 1 h) on AngII (100 nM, 1 h)-induced NADPH 
oxidase activity. (B) Effect of CLI-095 (1 µM, 1 h) on AngII (10 min)-induced p-
JNK1/2 protein expression; a representative blot is shown above. (C) Effect of CLI-095 
on nuclear p65 NF-κB protein expression induced by AngII (45 min); representative 
blots of the cytosolic (Cy) and nuclear (Nu) expression are shown above; Histone-3 
(H3) expressions are also shown to guarantee the successful cellular fractioning. (D) 
Representative photomicrographs of p65 NF-κB immunofluorescence (red) in VSMC in 
control and after incubation with AngII in the absence and the presence of CLI-095. The 
insets are magnified images of indicated areas. Images were captured with a 
fluorescence microscope (×20 objective); image size: 444.16 x 332.8 µm. *P < 0.05 vs. 
Control, 
#
P < 0.05 vs. AngII. n=4-5. 
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Figure 8. TLR4 inhibition reduces the involvement of oxidative stress on 
vasoconstrictor responses in aorta from AngII-infused mice. Effect of catalase (1000 
U·ml
-1
), apocynin (0.3 mM), ML-171 (0.5 µM) and Mito-TEMPO (0.5 µM) on the 
concentration-response curve to phenylephrine (Phe) in aortic segments from mice 
treated with a non-specific IgG, with AngII plus a non-specific IgG or with AngII plus 
anti-TLR4 antibody. *P < 0.05. n=5-11. 
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Figure 9. TLR4 inhibition reduces the involvement of oxidative stress on 
vasodilator responses in aorta from AngII-infused mice. Effect of catalase (1000 
U·ml
-1
), apocynin (0.3 mM), ML-171 (0.5 µM) and Mito-TEMPO (0.5 µM) on the 
concentration-response curve to ACh in aortic segments from mice treated with a non-
specific IgG, with AngII plus a non-specific IgG or with AngII plus anti-TLR4 
antibody. * P < 0.05. n=5-11. 
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Figure 10. TLR4 inhibition increases NO production and its participation on 
vasoconstrictor responses in AngII-infused mice. (A) Quantification of NO release in 
aortic segments from mice treated with a non-specific IgG, with AngII plus a non-
specific IgG or with AngII plus anti-TLR4 antibody. (B) Effect of N
G
-nitro-L-arginine 
methyl ester (L-NAME, 100 µM) on the concentration-response curve to phenylephrine 
(Phe) in aortic segments from the three groups of mice. Differences of the area under 
the concentration-response curve (dAUC) to Phe in the presence and the absence of L-
NAME are also shown. *P < 0.05 vs Control or vs Control + IgG, 
#
P < 0.05 vs AngII + 
IgG. n=5-9. 
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Table 1 Effect of L-NAME on maximum response (Emax) and pD2 values of 
phenylephrine responses in aortic segments from mice treated with a non-specific IgG, 
with AngII plus a non-specific IgG or with AngII plus anti-TLR4 antibody. 
 
  Control L-NAME Fold increase 
Control + IgG 
Emax (%) 30.1 + 2.6 85.7 + 6.4* 2.84 + 0.21 
pD2 6.53 + 0.17 7.12 + 0.06* - 
AngII + IgG 
Emax (%) 89.6 + 4.2# 148.2 + 17.7*# 1.65 + 0.20
#
 
pD2 7.02 + 0.04
# 7.30 + 0.07* - 
AngII + anti-TLR4 
Emax (%) 44.8 + 8.7$ 103.7 + 9.8*$ 2.32 + 0.22$ 
pD2 6.72 + 0.08$ 7.02 + 0.07*$ - 
 
The enhancing effect of L-NAME in Emax is expressed as fold increase over control 
situation.*P < 0.05 vs Control; 
#
P < 0.05 vs Control + IgG mice; 
$
P <0.05 vs Ang + IgG 
mice; n=5-9. 
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